Shilpa Medicare announces receipt of CEP from EDQM for API ‘Desmopressin’ | Capital Market News

Shilpa Medicare’s 100% subsidiary, Shilpa Pharma Lifesciences received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Desmopressin.

Desmopressin is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis. Desmopressin helps to reduce frequent urination and excessive thirst. This is used to treat central diabetes insipidus and bedwetting.

Click here to connect with us on WhatsApp

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content